硝唑尼特老药新用治疗银屑病:通过皮肤代谢重编程发挥疗效
该研究探索FDA已批准抗寄生虫药硝唑尼特(NTZ)对银屑病的治疗作用及机制。采用咪喹莫特诱导的小鼠银屑病样皮炎模型和IL-17刺激的人角质形成细胞,发现NTZ抑制IL-17介导的代谢程序转换、葡萄糖摄取和氧化磷酸化增强,通过AMPK抑制mTOR并减少损伤线粒体积累,同时抑制Th17炎症反应。结果为NTZ治疗银屑病提供临床前证据。
要点
- NTZ抑制IL-17诱导的角质形成细胞糖摄取和氧化磷酸化增强。
- NTZ经AMPK抑制mTOR,减少高线粒体质量和高ROS的损伤线粒体。
- 小鼠模型中NTZ抑制损伤线粒体积累和Th17介导的炎症反应。
核心结论
- NTZ通过皮肤代谢重编程抑制IL-17介导的炎症,为银屑病治疗提供临床前证据。
- 靶向皮肤能量代谢通路可能有益于银屑病的治疗和预防。
研究设计与样本
- 使用咪喹莫特诱导的银屑病样皮肤炎症小鼠模型。
- 使用IL-17刺激的人角质形成细胞进行体外研究。
主要发现
- NTZ抑制IL-17介导炎症在人角质形成细胞中诱导的代谢程序转换。
- NTZ抑制IL-17刺激的葡萄糖摄取及相关作用,并降低增强的氧化磷酸化。
- NTZ通过诱导AMPK抑制mTOR信号通路。
- NTZ防止以高线粒体质量和高ROS水平为特征的损伤线粒体发展。
- 小鼠模型中NTZ抑制损伤线粒体积累和Th17介导的炎症反应。
临床怎么用
- NTZ作为FDA已批准药物,具有老药新用治疗银屑病的转化潜力。
- 靶向皮肤能量代谢通路可能成为银屑病治疗与预防的新策略。
局限性
- 研究仅为临床前证据,尚未在银屑病患者中验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nitazoxanide (NTZ), a Food and Drug Administration-approved drug, was originally developed for the treatment of parasitic infections. Recent studies have revealed that NTZ may also be effective in treating other diseases, including inflammatory diseases, cancer, and bacterial and viral infections. Therefore, we investigated whether NTZ could inhibit specific inflammatory pathways and reprogram metabolic processes in psoriasis to regulate inflammation. To investigate the symptom-alleviating effects of NTZ on psoriasis and its underlying mechanisms, we used an imiquimod-induced psoriatic-like skin inflammation mouse model and IL-17-stimulated human keratinocytes. NTZ inhibited the transition of metabolic programs induced by IL-17-mediated inflammation in human keratinocytes. In particular, NTZ suppressed glucose uptake and the associated actions stimulated by IL-17 and reduced enhanced oxidative phosphorylation. NTZ inhibited the mTOR signaling pathway by inducing AMP-activated protein kinase and prevented the development of dysfunctional mitochondria characterized by high mitochondrial mass and high levels of ROS. Moreover, the administration of NTZ in a mouse model of psoriasis, an IL-17-mediated skin disease, inhibited the accumulation of damaged mitochondria and suppressed T helper 17-mediated inflammatory responses. These findings provide preclinical evidence that NTZ may be effective in treating psoriasis and suggest that targeting the energy metabolic pathways in the skin could be beneficial for the treatment and prevention of psoriasis.
引用
- Lee JY, Kim HE, Lee ST, et al. The Repurposing of Nitazoxanide for Psoriasis Treatment Exerts Therapeutic Effects through Skin Metabolic Reprogramming. J Invest Dermatol. 2025. PMID: 40043790. doi:10.1016/j.jid.2025.02.137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。